Attached files

file filename
8-K - FORM 8-K - XENONICS HOLDINGS, INC.d584521d8k.htm

Exhibit 99.1

 

LOGO   

Investor Contact:

Berkman Associates

(310) 477 - 3118

info@BerkmanAssociates.com

  

Company Contact:

Alan Magerman, Chairman

(760) 477 - 8900

xenonics@xenonics.com

Xenonics Reports Third Quarter Results

CARLSBAD, CALIFORNIA — August 14, 2013 — XENONICS HOLDINGS, INC. (OTCBB:XNNH) today announced financial results for the third quarter and first nine months of fiscal 2013.

Revenue for the three months ended June 30, 2013 decreased to $373,000, compared to $403,000 for the third quarter of fiscal 2012. The net loss for the third quarter of fiscal 2013 was $480,000, or $0.02 per share. This compares to a net loss for the third quarter of fiscal 2012 of $630,000, or $0.03 per share.

For the nine months ended June 30, 2013, revenue increased to $1,492,000, compared to $1,200,000 for the first nine months of fiscal 2012. The net loss for this year’s first nine months decreased to $1,267,000, or $0.05 per share. This compares to a net loss for the first nine months of fiscal 2012 of $1,857,000, or $0.07 per share.

Selling, general and administrative expenses decreased by 28% to $380,000 for the third quarter of fiscal 2013 from $527,000 for the third quarter of fiscal 2012. For the first nine months, SG&A decreased to $1,264,000, compared to $1,587,000 for the same period of the prior fiscal year.

At June 30, 2013, Xenonics reported total current assets of $2,030,000, including cash of $185,000, accounts receivable of $60,000, and inventories of $1,740,000. Total current liabilities at June 30, 2013 of $2,510,000 included notes payable of $1,898,000 due in October 2013.

“We expect to ship in the current quarter approximately $900,000 of the $1.2 million NightHunter purchase order we received from Aardvark Tactical last May. We are pursuing additional orders for our NightHunter and SuperVision products,” said Chairman Alan Magerman.

Conference Call

Xenonics has scheduled a conference call at 11:00 a.m. EDT this morning to discuss its results for the third quarter of fiscal 2013. The dial-in number is (877) 703-6109, passcode #72336076. A simultaneous webcast of the conference call can be accessed from the Webcast Center of the Investor Relations link at www.xenonics.com. A replay will be available after 1:00 p.m. EDT at this same Internet address. For a telephone replay, dial (888) 286-8010, passcode #73595683, after 1:00 p.m. EDT.

About Xenonics

Xenonics Holdings, Inc. develops and produces advanced, lightweight and compact ultra-high-intensity illumination and low-light vision products for military, law enforcement, public safety, and commercial and private sector applications. Xenonics’ NightHunter line of illumination products is used by every branch of the U.S. Armed Forces as well as law enforcement and security agencies. Its SuperVision high-definition night vision is designed for commercial and military applications. Employing patented technologies, Xenonics provides innovative solutions for customers who must see farther so they can do their jobs better and safer. Xenonics’ products represent the next generation in small, high intensity, high efficiency illumination and low-light vision systems. Visit Xenonics on the web at www.xenonics.com.

Forward-Looking Statements

Except for the historical statements, statements in this release may constitute forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934. When used, the words “anticipates,” “believes,” “expects,” “intends,” “future,” and other similar expressions identify forward-looking statements. These forward-looking statements reflect management’s current views with respect to future events and financial performance and are subject to risks and uncertainties, and actual results may differ materially from the outcomes contained in any forward-looking statement. Factors that could cause these forward-looking statements to differ from actual results include delays in development, marketing or sales of new products, and other risks and uncertainties discussed in the company’s periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. Xenonics Holdings undertakes no obligation to update or revise any forward-looking statements.

(tables attached)

3186 Lionshead Avenue, Carlsbad, CA 92010

(760) 477-8900 fax (760) 477-8896 www.xenonics.com email xenonics@xenonics.com


XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

     Three months ended     Nine months ended  
     June 30,     June 30,  
     2013     2012     2013     2012  
Rounded in thousands, except per share amounts    (unaudited)     (unaudited)  

Revenue

   $ 373,000     $ 403,000     $ 1,492,000     $ 1,200,000  

Cost of goods sold

     247,000       254,000       826,000       741,000  
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     126,000       149,000       666,000       459,000  

Selling, general and administrative

     380,000       527,000       1,264,000       1,587,000  

Research and development

     99,000       191,000       327,000       588,000  
  

 

 

   

 

 

   

 

 

   

 

 

 

Income (loss) from operations

     (353,000     (569,000     (925,000     (1,716,000

Other income (expense):

        

Interest (expense)

     (127,000     (61,000     (340,000     (139,000
  

 

 

   

 

 

   

 

 

   

 

 

 

(Loss) before provision for income taxes

     (480,000     (630,000     (1,265,000     (1,855,000

Income tax provision

     —         —         2,000       2,000  
  

 

 

   

 

 

   

 

 

   

 

 

 

Net (loss)

   $ (480,000   $ (630,000   $ (1,267,000   $ (1,857,000
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income (loss) per share:

        

Basic

   $ (0.02   $ (0.03   $ (0.05   $ (0.07
  

 

 

   

 

 

   

 

 

   

 

 

 

Fully-diluted

   $ (0.02   $ (0.03   $ (0.05   $ (0.07
  

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding:

        

Basic

     24,976,000       24,976,000       24,976,000       24,976,000  
  

 

 

   

 

 

   

 

 

   

 

 

 

Fully diluted

     24,976,000       24,976,000       24,976,000       24,976,000  
  

 

 

   

 

 

   

 

 

   

 

 

 


XENONICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

     June 30,     September 30,  
     2013     2012  
Rounded in thousands, except par value    (unaudited)        
Assets     

Current Assets:

    

Cash

   $ 185,000     $ 367,000  

Accounts receivable

     60,000       58,000  

Inventories

     1,740,000       2,117,000  

Other current assets

     45,000       82,000  
  

 

 

   

 

 

 

Total Current Assets

     2,030,000       2,624,000  

Equipment, furniture and fixtures, net

     14,000       14,000  

Goodwill

     375,000       375,000  

Other assets

     17,000       17,000  
  

 

 

   

 

 

 

Total Assets

   $ 2,436,000     $ 3,030,000  
  

 

 

   

 

 

 

Liabilities and Shareholders’ Equity

    

Current Liabilities:

    

Accounts payable

   $ 360,000     $ 281,000  

Accrued expenses

     191,000       134,000  

Accrued payroll and related taxes

     61,000       95,000  

Notes payable, net of debt discount

     1,898,000       1,000,000  
  

 

 

   

 

 

 

Total Current Liabilities

     2,510,000       1,510,000  

Notes payable

     —         525,000  
  

 

 

   

 

 

 

Total Liabilities

     2,510,000       2,035,000  
  

 

 

   

 

 

 

Commitments and contingencies (Note 11)

    

Shareholders’ Equity:

    

Preferred shares, $0.001 par value, 5,000,000 shares authorized, 0 shares issued and  outstanding

     —         —    

Common shares, $0.001 par value, 50,000,000 shares authorized; 24,976,000 shares issued and outstanding at June 30, 2013 and September 30, 2012

     25,000       25,000  

Additional paid-in capital

     26,879,000       26,681,000  

Accumulated deficit

     (26,978,000     (25,711,000
  

 

 

   

 

 

 

Total Shareholders’ Equity (Deficit)

     (74,000     995,000  
  

 

 

   

 

 

 

Total Liabilities and Shareholders’ Equity

   $ 2,436,000     $ 3,030,000